Skip to main content
Premium Trial:

Request an Annual Quote

Accelerate Dx Posts Increase in Q2 Revenues, Net Loss

NEW YORK (GenomeWeb) - Accelerate Diagnostics today said that revenues for its second quarter rose 46 percent.

According to a document filed with the US Securities and Exchange Commission, for the three months ended June 30, the Tucson, Arizona-based molecular diagnostics company said that revenues increased to $19,000 from $13,000 a year ago, composed entirely of revenues associated with licensing agreements.

The firm's net loss in the quarter was $12.3 million, or $.27 per share, compared to a net loss of $8.2 million, or $.19 per share, in the prior-year period.

Accelerate Diagnostics' R&D spending rose to $7.1 million, up 56 percent from $4.6 million during the second quarter of 2014, driven by new hires and increased purchases of laboratory and instrument engineering supplies to support R&D. Its SG&A costs rose 38 percent to $4.8 million from $3.4 million, driven by increases in salaries and related expenses as the firm ramped up operations.

Accelerate Diagnostics ended the quarter with $35.2 million in cash and cash equivalents.

In mid-day trade Monday on the Nasdaq, shares of Accelerate Dx were down 8 percent at $25.65.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.